Trial Profile
Lenalidomide Following Rituximab and Fludarabine in Untreated Chronic Lymphocytic Leukemia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Fludarabine; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 03 Apr 2012 Actual patient number 21 added as reported by ClinicalTrials.gov.
- 03 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.